Genetic Technologies (NASDAQ:GENE) Shares Up 1%

Genetic Technologies Limited (NASDAQ:GENE) traded up 1% on Tuesday . The company traded as high as $2.28 and last traded at $1.88, 14,388 shares traded hands during trading. A decline of 63% from the average session volume of 39,034 shares. The stock had previously closed at $1.86.

Separately, ValuEngine lowered Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Monday, May 13th.

The company has a fifty day moving average of $0.79 and a 200-day moving average of $0.80.

An institutional investor recently bought a new position in Genetic Technologies stock. Alpine Group USVI LLC acquired a new position in shares of Genetic Technologies Limited (NASDAQ:GENE) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies accounts for approximately 0.1% of Alpine Group USVI LLC’s portfolio, making the stock its 15th biggest position. Alpine Group USVI LLC owned 0.18% of Genetic Technologies as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Genetic Technologies Company Profile (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Featured Article: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.